Orbimed Advisors LLC Fate Therapeutics Inc Transaction History
Orbimed Advisors LLC
- $4.24 Billion
- Q3 2024
A detailed history of Orbimed Advisors LLC transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Orbimed Advisors LLC holds 1,680,580 shares of FATE stock, worth $2.82 Million. This represents 0.14% of its overall portfolio holdings.
Number of Shares
1,680,580
Previous 1,355,352
24.0%
Holding current value
$2.82 Million
Previous $4.45 Million
32.33%
% of portfolio
0.14%
Previous 0.11%
Shares
3 transactions
Others Institutions Holding FATE
# of Institutions
175Shares Held
115MCall Options Held
53.7KPut Options Held
9K-
Redmile Group, LLC San Francisco, CA13.2MShares$22.1 Million3.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.4MShares$17.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$17 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT5.57MShares$9.36 Million0.72% of portfolio
-
State Street Corp Boston, MA5.25MShares$8.82 Million0.0% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $163M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...